Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

NEW YORK (TheStreet) -- Gentlemen and ladies, start your engines: The best sectors in our economy have completed their first lap, Jim Cramer told his Mad Money viewers Monday, referring to the industrials, the oils and technology, all of which continue to rise off their August bottom.

Cramer said it's clear the last week of August was the bottom for these three important market sectors. That was when the Chinese stock market stopped falling and began to stabilize and it was when crude oil also found its footing. It was also around that time when companies including Apple (AAPL) - Get Report , a stock Cramer owns for his charitable trust, Action Alerts PLUS, and Nike (NKE) - Get Report informed the markets that the Chinese consumer is still spending, despite the precipitous fall in China's stock market.

Cramer said the markets are likely to retest the August lows, but he expects those levels to hold -- which will only buoy stocks further going into the end of the year.

Stunning Helen of Troy

When a company in which you have confidence hits a speed bump, have some conviction and stick with it, Cramer told viewers. Often times, you'll be rewarded handsomely.

That was certainly the case with Helen of Troy (HELE) - Get Report , the consumer packaged goods company that makes such brands as Oxo kitchen gadgets, Pur water filters, Pert shampoo and Vicks health and wellness items.

Cramer recommended Helen of Troy earlier this year and was seeing some nice gains when the company missed earnings on July 9, sending shares down a sharp 10%. But Cramer reiterated his recommendation shortly thereafter, noting that the analysts had simply gotten ahead of themselves and no company could've met the expectations they had set.

Flash forward to last Thursday, when Helen delivered a stunning 41-cents-a-share earnings beat. The stock is now up over 18% from its July lows.

Cramer reminded viewers that Helen breathes new life into tired brands and is a master at innovating and cutting costs. The stock still has a lot more room to run, he said, as shares trade at just 17.6 times earnings, which is still less than its peers. Don't forget that Helen of Troy derives 80% of its sales domestically, so is not hostage to overseas woes.

Buy Eli Lilly

The biotechs may be out of favor on the Wall Street fashion show, but there's one company, Eli Lilly (LLY) - Get Report , that now represents a fabulous buying opportunity.

Cramer said Lilly's 7.8% decline today on the news the company is halting a Phase III cardiovascular trial doesn't concern him in the least, because that drug wasn't even in the company's earnings forecasts.

Investors are buying Lilly for their diabetes and Alzheimer's franchises, Cramer continued, and both of those programs remain very strong. The anti-cholesterol drug in today's news, he said, was simply the icing on an otherwise delicious cake.

Bottom line, investors just got a chance to buy Eli Lilly at a terrific price, and they should take it.

Go With Energy Transfer

In today's tricky energy market, investors need stocks they can live with, Cramer told viewers. That's why Action Alert Plus holding Energy Transfer Partners (ETP) , with its 9% yield, remains his favorite pipeline master limited partnership.

Cramer said that Energy Transfer Equity's (ETE) acquisition of Williams Energy (WMB) - Get Report for $38 billion will be a game changer for for ETP, as it will give the company a national footprint and turn it into a powerhouse.

Cramer reminded viewers that ETP is not an oil producer like Linn Energy (LINE) , nor is it levered to the price of crude. That makes the decline in Energy Transfer's shares a huge buying opportunity and makes it a "must own" name.

Lightning Round

In the Lightning Round, Cramer was bullish on Hasbro (HAS) - Get Report and Boot Barn (BOOT) - Get Report .

Cramer was bearish on Ryder Systems (R) - Get Report and VMware (VMW) - Get Report .

Executive Decision: JJ Bienaime

For his "Executive Decision" segment, Cramer sat down with JJ Bienaime, CEO of orphan drug makerBioMarin Pharmaceuticals (BMRN) - Get Report ,

Bienaime commented on his company's recent win in a patent dispute with Sarepta Therapeutics (SRPT) - Get Report , calling the victory an important win for the protection of the company's intellectual property.

Bienaime also commented on the recent controversy surrounding drug pricing. He said that BioMarin is not in the business of repurposing old molecules and is instead developing important treatments for lethal diseases that have no other treatments and that would cost the healthcare system far more to manage over the long term.

For many of BioMarin's treatments, getting diagnosed early is important, Bienaime said, that's why his company is helping muscular dystrophy patients determine which mutation of the disease they have as early as possible so they can begin treatment.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.

At the time of publication, Cramer's Action Alerts PLUS had a position in AAPL and ETP.